3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
64
Lung Neoplasms
27
Triple Negative Breast Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
16
Breast Neoplasms
16
Small Cell Lung Carcinoma
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
12
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
12
Endometrial Neoplasms
11
Neoplasms
9
Neoplasm Metastasis
6
Carcinoma
6
Oropharyngeal Neoplasms
5
Urinary Bladder Neoplasms
4
Mouth Neoplasms
4
Lung Diseases
4
Laryngeal Neoplasms
4
Head and Neck Neoplasms
4
Colorectal Neoplasms
4
Adenocarcinoma of Lung
4
Uterine Cervical Neoplasms
3
Respiratory Tract Neoplasms
3
Prostatic Neoplasms
3
Mesothelioma
3
Hypopharyngeal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Central Nervous System Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Advanced Solid Tumors
3
Interventions
Carboplatin
2
repotrectinib
1
pembrolizumab
1
durvalumab
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Bronchogenic
×
Carboplatin
×
30 days
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled
NCT04564157
2026-05-05
NADIM-ADJUVANT
Fundación GECP
Phase 3
Active not recruiting
210 enrolled